TY - JOUR
T1 - Identification of head and neck squamous cell carcinoma biomarker candidates through proteomic analysis of cancer cell secretome
AU - Marimuthu, Arivusudar
AU - Chavan, Sandip
AU - Sathe, Gajanan
AU - Sahasrabuddhe, Nandini A.
AU - Srikanth, Srinivas M.
AU - Renuse, Santosh
AU - Ahmad, Sartaj
AU - Radhakrishnan, Aneesha
AU - Barbhuiya, Mustafa A.
AU - Kumar, Rekha V.
AU - Harsha, H. C.
AU - Sidransky, David
AU - Califano, Joseph
AU - Pandey, Akhilesh
AU - Chatterjee, Aditi
N1 - Funding Information:
We thank the Department of Biotechnology (DBT) of the Government of India for research support to the Institute of Bioinformatics, Bangalore, India. S.M.S, S.A. and S.R. are recipients of research fellowships from the University Grants Commission (UGC). G.S, S.C and A.R. are recipients of research fellowship from the Council of Scientific and Industrial Research, India (CSIR). Harsha Gowda is a Wellcome Trust/DBT India Alliance Early Career fellow. We thank Dr. S.K. Shankar and Dr. Anita Mahedavan at the National Institute of Mental Health and Neurosciences, Bangalore for providing access to the microscopic facility.
Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.
PY - 2013/11
Y1 - 2013/11
N2 - Protein biomarker discovery for early detection of head and neck squamous cell carcinoma (HNSCC) is a crucial unmet need to improve patient outcomes. Mass spectrometry-based proteomics has emerged as a promising tool for identification of biomarkers in different cancer types. Proteins secreted from cancer cells can serve as potential biomarkers for early diagnosis. In the current study, we have used isobaric tag for relative and absolute quantitation (iTRAQ) labeling methodology coupled with high resolution mass spectrometry to identify and quantitate secreted proteins from a panel of head and neck carcinoma cell lines. In all, we identified 2,472 proteins, of which 225 proteins were secreted at higher or lower abundance in HNSCC-derived cell lines. Of these, 148 were present in higher abundance and 77 were present in lower abundance in the cancer-cell derived secretome. We detected a higher abundance of some previously known markers for HNSCC including insulin like growth factor binding protein 3, IGFBP3 (11-fold) and opioid growth factor receptor, OGFR (10-fold) demonstrating the validity of our approach. We also identified several novel secreted proteins in HNSCC including olfactomedin-4, OLFM4 (12-fold) and hepatocyte growth factor activator, HGFA (5-fold). IHC-based validation was conducted in HNSCC using tissue microarrays which revealed overexpression of IGFBP3 and OLFM4 in 70% and 75% of the tested cases, respectively. Our study illustrates quantitative proteomics of secretome as a robust approach for identification of potential HNSCC biomarkers. This article is part of a Special Issue entitled: An Updated Secretome.
AB - Protein biomarker discovery for early detection of head and neck squamous cell carcinoma (HNSCC) is a crucial unmet need to improve patient outcomes. Mass spectrometry-based proteomics has emerged as a promising tool for identification of biomarkers in different cancer types. Proteins secreted from cancer cells can serve as potential biomarkers for early diagnosis. In the current study, we have used isobaric tag for relative and absolute quantitation (iTRAQ) labeling methodology coupled with high resolution mass spectrometry to identify and quantitate secreted proteins from a panel of head and neck carcinoma cell lines. In all, we identified 2,472 proteins, of which 225 proteins were secreted at higher or lower abundance in HNSCC-derived cell lines. Of these, 148 were present in higher abundance and 77 were present in lower abundance in the cancer-cell derived secretome. We detected a higher abundance of some previously known markers for HNSCC including insulin like growth factor binding protein 3, IGFBP3 (11-fold) and opioid growth factor receptor, OGFR (10-fold) demonstrating the validity of our approach. We also identified several novel secreted proteins in HNSCC including olfactomedin-4, OLFM4 (12-fold) and hepatocyte growth factor activator, HGFA (5-fold). IHC-based validation was conducted in HNSCC using tissue microarrays which revealed overexpression of IGFBP3 and OLFM4 in 70% and 75% of the tested cases, respectively. Our study illustrates quantitative proteomics of secretome as a robust approach for identification of potential HNSCC biomarkers. This article is part of a Special Issue entitled: An Updated Secretome.
KW - Body fluids
KW - In vitro labeling
KW - Oral carcinoma
UR - http://www.scopus.com/inward/record.url?scp=84884672483&partnerID=8YFLogxK
U2 - 10.1016/j.bbapap.2013.04.029
DO - 10.1016/j.bbapap.2013.04.029
M3 - Article
C2 - 23665456
AN - SCOPUS:84884672483
SN - 1570-9639
VL - 1834
SP - 2308
EP - 2316
JO - Biochimica et Biophysica Acta - Proteins and Proteomics
JF - Biochimica et Biophysica Acta - Proteins and Proteomics
IS - 11
ER -